Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins ...

Health Canada has granted approval for Novo Nordisk’s weight-loss drug, Wegovy. Wegovy now becomes the first treatment in Canada to address both obesity and the risk of heart-related issues in ...

In the latest trading session, Novo Nordisk (NVO) closed at $108.82, marking a -0.14% move from the previous day. The stock exceeded the S&P 500, which registered a loss of 0.19% for the day.

told the meeting that the promising results justify further research and a larger phase 2 trial is planned for the second half of this year, with results expected in around 2026. Novo Nordisk’s ...

ROCHESTER, N.Y. — Medical history is being made at Rochester General Hospital with the first U.S. clinical trial for a new heart failure therapy. Rochester General Hospital is testing “Aqua ...

Catalent and Novo Holdings—a holding company distinct from the Danish drugmaker Novo Nordisk—said the European Commission (EC) has granted “unconditional approval” to the companies ...

the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $16.5 billion for Catalent, a leading contract drug manufacturer. By taking this step, the executive arm ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...